20.500.12556/DiRROS-30010 FLAG/FLAG-Ida Regimen in secondary and relapsed/refractory acute myeloid leukemia—even in the era of new treatment modalities still a significant player Abstract: (1) Background: Relapsed/refractory (r/r) and secondary acute myeloid leukemia are highlighted by chemoresistance and poor outcomes. The aim of the study was to assess the efficacy and toxicity of fludarabine, cytarabine, and granulocyte-colony stimulation factor (FLAG) with or without idarubicin (-Ida) and to discuss novel therapies in this setting. (2) Methods: Clinical and cytogenetic data on 130 consecutive patients with r/r and secondary AML treated at our center were retrospectively analyzed. (3) Results: There were 48, 56, and 26 patients with relapsed, refractory, and secondary AML, respectively. The median age was 60 years. The overall response was achieved in 70% of patients. The median overall survival (OS) time for the whole group was 9.4 months. In total, 47% of patients proceeded to allogeneic hematopoietic stem cell transplantation (aHSCT) and these patients had significantly prolonged OS compared to the others (63 months vs. 4.2 months; p < 0.001). Among the variables, including age, FLT3 mutation status, European LeukemiaNet (ELN) 2022 classification risk, FLAG vs. FLAG-Ida, and aHSCT, a multivariate analysis revealed that only aHSCT significantly influenced overall survival. (4) Conclusions: FLAG(-Ida) chemotherapy remains an effective salvage chemotherapy for patients with r/r and secondary AML with a plan of proceeding to aHSCT. relapsed/refractory AML secondary AML FLAG-Ida FLAG FLT3 mutation true false true Angleški jezik Ni določen Neznano 2026-06-11 13:03:56 2026-06-11 13:03:56 2026-06-12 03:54:44 0000-00-00 00:00:00 2024 0 0 Nasl. z nasl. zaslona; Opis vira z dne 29. 3. 2024; str. 1-10 iss. 2, [article no.] 1842 Vol. 13 2024 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 61 2077-0383 10.3390/jcm13071842 190952195 RAZ_Anzej_Doma_Sasa_2024.pdf RAZ_Anzej_Doma_Sasa_2024.pdf 1 39DDCB9E626A816CE51C3CD4DF02A908 a92f7b3d3da656bf78f4a499f7038864a30a3ddf7c89437b9bc568b96ed9fcb1 56ef48d6-6585-11f1-9215-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=45227 https://www.mdpi.com/2077-0383/13/7/1842 1 3e75c389-6585-11f1-9215-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=45226 Univerzitetni klinični center Ljubljana 0 0 0